Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers

被引:32
|
作者
Allqvist, Annika [1 ]
Miura, Jun [1 ]
Bertilsson, Leif [1 ]
Mirghani, Rajaa A. [1 ]
机构
[1] Karolinska Univ Hosp, Div Clin Pharmacol, Dept Lab Med, Karolinska Inst, S-14186 Huddinge, Stockholm, Sweden
关键词
alprazolam; CYP3A4; CYP3A5; ketoconazole; quinine;
D O I
10.1007/s00228-006-0230-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective The antifungal drug ketoconazole (KTZ) is known as an inhibitor of, especially, the CYP3A subfamily, which catalyzes the metabolism of a large variety of drugs. Interactions between KTZ and CYP3A substrates have been reported both in vivo and in vitro. Most of them, however, involved the KTZ racemate. KTZ racemate and the separate enantiomers, 2R,4R; 2R,4S; 2S,4S, and 2S,4R, were evaluated for their selectivity in inhibiting alprazolam and quinine metabolism. Methods The inhibition of alprazolam and quinine metabolism was studied in an in vitro system of human liver microsomes (HLM), recombinant of CYP3A4 and CYP3A5. The concentrations of formed 3-hydroxyquinine and 4- and alpha-hydroxyalprazolam were measured by HPLC and LC-MS, respectively. Results Quinine 3-hydroxylation was catalyzed to a similar extent by CYP3A4 and CYP3A5. The formation rate of 4-hydroxyalprazolam was higher than that of alpha-hydroxyalprazolam for each HLM, CYP3A4 and CYP3A5. KTZ racemate and enantiomers showed differential inhibitory effects of quinine and alprazolam metabolism. Quinine metabolism catalyzed by HLM, CYP3A4 and CYP3A5 was potently inhibited by the trans-enantiomer KTZ 2S,4S, with IC50 value of 0.16 mu M for HLM, 0.04 mu M for CYP3A4 and 0.11 mu M for CYP3A5. The same enantiomer showed the lowest IC50 values of 0.11 mu M for HLM and 0.04 mu M for CYP3A5 with respect to alprazoalm 4-hydroxylation and also the same pattern for alprazolam alpha-hydroxylation, 0.13 mu M for HLM and 0.05 mu M for CYP3A5. Alprazolam metabolism (both alpha- and 4- hydroxylations) catalyzed by CYP3A4 was inhibited potently by the cis-enantiomer KTZ 2S,4R, with IC50 values of 0.03 mu M . Conclusions Alprazolam and quinine metabolism is catalyzed by both CYP3A4 and CYP3A5. The present study showed that different KTZ enantiomers inhibit CYP3A4 and CYP3A5 to different degrees, indicating that structural differences among the enantiomers would be related to their inhibitory potency on these two enzymes.
引用
收藏
页码:173 / 179
页数:7
相关论文
共 50 条
  • [1] Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers
    Annika Allqvist
    Jun Miura
    Leif Bertilsson
    Rajaa A. Mirghani
    European Journal of Clinical Pharmacology, 2007, 63 : 173 - 179
  • [2] In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans
    Hirota, N
    Ito, K
    Iwatsubo, T
    Green, CE
    Tyson, CA
    Shimada, N
    Suzuki, H
    Sugiyama, Y
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2001, 22 (02) : 53 - 71
  • [3] Comparative drug metabolism by CYP3A4 and CYP3A5
    Huang, WL
    Lin, YS
    Dai, Y
    Totah, RA
    Calamia, JC
    Thummel, KE
    DRUG METABOLISM REVIEWS, 2003, 35 : 187 - 187
  • [4] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism
    McGraw, Joseph
    Cherney, Mitchell
    Bichler, Katherine
    Gerhardt, Armin
    Nauman, Mirielle
    TOXICOLOGY LETTERS, 2019, 315 : 9 - 13
  • [5] Differential inhibition of CYP3A4 and CYP3A5 by verapamil.
    Wang, Y
    Jones, DR
    Hall, SD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P16 - P16
  • [6] The Relative Contributions of CYP3A4 and CYP3A5 to the Metabolism of Vinorelbine
    Topletz, Ariel R.
    Dennison, Jennifer B.
    Barbuch, Robert J.
    Hadden, Chad E.
    Hall, Stephen D.
    Renbarger, Jamie L.
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (09) : 1651 - 1661
  • [7] CYP3A4 and CYP3A5 genotyping by pyrosequencing
    Garsa, AA
    McLeod, HL
    Marsh, S
    BMC MEDICAL GENETICS, 2005, 6
  • [8] Comparison of CYP3A4 and CYP3A5 in Drug Metabolism and Drug Interactions
    Li, Shuanmei
    Liu, Duan
    Zhu, Juanli
    Cui, Yan
    Zhou, Ruimin
    Chen, Chao
    DRUG METABOLISM REVIEWS, 2009, 41 : 31 - 32
  • [9] Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: Differential metabolism by CYP3A4 and CYP3A5
    Cook, CS
    Berry, LM
    Kim, DH
    Burton, EG
    Hribar, JD
    Zhang, LM
    DRUG METABOLISM AND DISPOSITION, 2002, 30 (12) : 1344 - 1351
  • [10] USE OF THE CYP3A4 SELECTIVE INHIBITOR CYP3CIDE IN CYP3A5 GENOTYPED CRYOPRESERVED HUMAN HEPATOCYTES TO EXPLORE THE INDIVIDUAL CONTRIBUTION OF CYP3A4 AND CYP3A5 IN DRUG METABOLISM
    Heyward, Scott
    Schultz, Rachel N. V.
    Dennell, Stephen
    DRUG METABOLISM REVIEWS, 2014, 45 : 135 - 136